Sai Parenteral's intimates exchanges of its April 20, 2026 board meeting under SEBI LODR Regulation 29(1)(d).
Board to consider investing in/lending to Australian step-down subsidiary Noumed Pharmaceuticals Pty Limited.
Proposed investment will be routed through wholly-owned subsidiary Sai Parenterals PTE Limited.